Sustainability

While ESG is still in the early stages for pharma, many companies are moving forward with a need for compliance.

Examining efforts to boost women representation on company boards.

The validity of ESG-driven investment and reporting in healthcare.

Reaching new heights in sustainability a win-win for industry.

Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.

A prime opportunity for pharma to raise its strategic game in ESG.

Adam Carter discusses the causes and potential solutions to the pharma industry's sustainability issues.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

How principles of both can help companies navigate future storms.

Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.

Instead, incorporate ESG into your long-term business planning.

Rise in demand for sustainable practices forces industry to be more proactive.

New regulations set stage for updated ESG considerations.

Why purpose-driven firms are now more important than ever.

Small companies that want to develop an environmental, social, and corporate governance (ESG) program should start the process by defining their goals and identifying the initiatives that their peers and competitors tend to focus on.

Elizabeth (EJ) Ashbourne, Executive Director of the Partnership for Quality Medical Donations (PQMD), discusses the role of the organization in advancing global health and highlights the benefits offered to members of the pharma industry.

Strategies to become a Certified B Corporation, and the benefits to the industry, its stakeholders, and the world.

Meaningful biopharma sustainability metrics are a crucial challenge.

Biopharma sustainability resolutions for a better 2021.

For many years, high energy use and its impact on the environment by businesses within the life sciences sector had been generally overlooked in national and global efforts to combat climate change. But with “carbon neutrality” the new buzzwords, how is the sector embracing this push for change?

Why major companies are stepping up environmental commitments.

SynBio opens new environmental sustainability possibilities for pharma.

Especially critical amid the continuing global pandemic, key metrics are laid out to help life sciences companies define, measure, and effectively communicate sustainability practices and progress—and build foundations for long-term business value.

Biopharma must find sustainable models for public policy engagement.

ESG objectives are integral to long-term biopharma strategy.

The need for clear transparency around use of real-world data, AI.

Three areas critical to ensuring meaningful long-term action.

Guidance addresses struggles in reporting non-financial performance.

The commercial and social value of non-financial performance.